Rapport Therapeutics, Inc. (RAPP)
| Market Cap | 660.94M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -71.85M |
| Shares Out | 36.58M |
| EPS (ttm) | -5.81 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 506,474 |
| Open | 17.57 |
| Previous Close | 17.86 |
| Day's Range | 17.52 - 19.09 |
| 52-Week Range | 16.55 - 29.74 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 37.33 (+106.59%) |
| Earnings Date | Feb 10, 2025 |
About RAPP
Rapport Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule medicines for patients suffering from central nervous system (CNS) disorders. Its lead product candidate is receptor associated protein (RAP)-219, an investigational small molecule that is designed to inhibit TARPy8-containing AMPARs with picomolar affinity for the treatment of focal epilepsy and other CNS disorders, including peripheral neuropathic pain and bipolar disorder. The company also develops RAP-199, a TAR... [Read more]
Analyst Forecast
According to 4 analysts, the average rating for RAPP stock is "Strong Buy." The 12-month stock price forecast is $37.33, which is an increase of 106.59% from the latest price.
News
Rapport Therapeutics Presents Data Demonstrating Consistent Association Between Decreases in RNS Measured Long Episodes and Meaningful Reductions in Clinical Seizures
A 30% reduction in long episodes was shown to be associated with a 50% or greater reduction in clinical seizures in a post-hoc analysis, validating the biomarker for proof-of-concept studies Change in...
Rapport Therapeutics to Present Data at American Epilepsy Society Annual Meeting
Poster presentations on Phase 2a trial seizure biomarker, preclinical, and Phase 1 clinical data Poster presentations on Phase 2a trial seizure biomarker, preclinical, and Phase 1 clinical data
Rapport Therapeutics to Present at Stifel Healthcare Conference and Jefferies London Healthcare Conference in November
BOSTON and SAN DIEGO, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP), a clinical-stage biotechnology company focused on discovery and development of small molecule precisi...
This Rapport Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
Rapport semestriel Pilier 3 - 30 juin 2024
Veuillez trouver ci-joint le rapport annuel Pilier 3 au 30 juin 2024 Attachment Rapport semestriel Pilier 3 - 30 juin 2024
Rapport Therapeutics to Present at Upcoming Epilepsy Medical Conferences
BOSTON and SAN DIEGO, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP), a clinical-stage biotechnology company focused on discovery and development of transformational smal...
Rapport Therapeutics to Present at 22nd Annual Morgan Stanley Global Healthcare Conference and TD Cowen's 4th Annual Novel Mechanisms in Neuropsychiatry Summit
BOSTON and SAN DIEGO, Aug. 29, 2024 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP), a clinical-stage biotechnology company focused on discovery and development of transformational small...
Rapport Therapeutics to Present Data for TARPγ8 AMPAR Negative Modulator at IASP 2024 World Congress on Pain
Preclinical data on TARPγ8 targeted compound, an analog to Rapport's lead product candidate RAP-219, demonstrated analgesic activity in multiple pain models Preclinical data on TARPγ8 targeted compoun...
Rapport Therapeutics Announces Closing of $174 Million Initial Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares and Concurrent Private Placement
BOSTON and SAN DIEGO, June 12, 2024 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP), a clinical-stage biotechnology company focused on discovery and development of transformational small...
J&J-backed Rapport Therapeutics valued at $636.8 mln after shares rise 6% in debut
Shares of Rapport Therapeutics , backed by Johnson & Johnson's venture capital arm, rose nearly 6% in their market debut on Friday, valuing the early stage therapy developer at $636.8 million.
J&J-backed Rapport Therapeutics raises $136 mln in US IPO
Rapport Therapeutics said on Thursday that it has raised $136 million in its initial public offering in the United States at a valuation of about $601.4 million.
Rapport Therapeutics Announces Pricing of Initial Public Offering
BOSTON and SAN DIEGO, June 06, 2024 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP), a clinical-stage biotechnology company focused on discovery and development of transformational small...
J&J-backed Rapport Therapeutics seeks about $637 mln valuation in US IPO
Rapport Therapeutics is targeting a valuation of about $637 million in its initial public offering in the United States, as the biopharmaceutical company joins a slew of firms looking to list their sh...
Rapport Therapeutics Seeks IPO For CNS Treatment Programs
Rapport Therapeutics, Inc. has filed for a $100 million IPO to develop treatment candidates for central nervous system and related disorders. The company's lead candidate, RAP-219, is being developed ...
J&J-backed startup Rapport files for US IPO
Biopharmaceutical company Rapport Therapeutics, backed by the venture capital arm of Johnson & Johnson , filed for an initial public offering in the United States on Friday.
CNS disorder biotech Rapport Therapeutics files for a $100 million IPO
Rapport Therapeutics, a Phase 2-ready biotech developing small molecule therapies for CNS disorders, filed on Friday with the SEC to raise up to $100 million in an initial public offering.
Rapport Therapeutics IPO Registration Document (S-1)
Rapport Therapeutics has filed to go public with an IPO on the NASDAQ.